About BioFluidica

BioFluidica's LiquidScan is the future of liquid biopsy. LiquidScan combines cutting-edge microfluidics and automation hardware for precision medicine for multiple cancers and prenatal diagnostics testing. LiquidScan isolates and enriches rare cells and exosomes from liquid biopsy samples.

HER2+ Breast Cancer Pilot Study

February 9, 2023 Blood was drawn from 16 breast cancer patients and enriched for Circulating Tumor Cells (CTCs) using LiquidScan. Isolated cells were analyzed for HER2 positivity [Read More...]

HER2+ Breast Cancer Pilot Study2023-03-22T10:49:30-07:00
Go to Top